41 – 50 of 91
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2011
-
Mark
The need for speed in the management of haemophilia patients with inhibitors
(
- Contribution to journal › Article
- 2010
-
Mark
FEIBA prophylaxis in haemophilia patients: a clinical update and treatment recommendations
(
- Contribution to journal › Article
-
Mark
Inhibition of Human DHODH by 4-Hydroxycoumarins, Fenamic Acids, and N-(Alkylcarbonyl)anthranilic Acids Identified by Structure-Guided Fragment Selection
(
- Contribution to journal › Article
- 2009
-
Mark
Impact of polymorphisms of the major histocompatibility complex class II, interleukin-10, tumor necrosis factor-alpha and cytotoxic T-lymphocyte antigen-4 genes on inhibitor development in severe hemophilia A
(
- Contribution to journal › Article
-
Mark
Effect of rFVIIa dose and time to treatment on patients with haemophilia and inhibitors: analysis of HemoRec registry data from the Czech Republic
(
- Contribution to journal › Article
-
Mark
Crystal structure of the parasite inhibitor chagasin in complex with papain allows identification of structural requirements for broad reactivity and specificity determinants for target proteases
(
- Contribution to journal › Article
-
Mark
Paediatric haemophilia with inhibitors: existing management options, treatment gaps and unmet needs
(
- Contribution to journal › Scientific review
- 2008
-
Mark
From theory to practice: Applying current clinical knowledge and treatment strategies to the care of hemophilia A patients with inhibitors
(
- Contribution to journal › Scientific review
-
Mark
Secondary prophylaxis with recombinant activated factor VII improves health-related quality of life of haemophilia patients with inhibitors
(
- Contribution to journal › Article
-
Mark
Prevention of arthropathy: may it be extrapolated from patients without inhibitors to patients with inhibitors?
(
- Contribution to journal › Article